[Treatment of steroid-refractory ulcerative colitis with infliximab].
Castro Fernández
M
M
García Díaz
E
E
Romero
M
M
Galán Jurado
V
V
Rodríguez Alonso
C
C
D000328:Adult; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001803:Blood Transfusion; D019819:Budesonide / Q000494:pharmacology / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004750:Enteral Nutrition; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D019804:Mesalamine / Q000627:therapeutic use; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D019804:Mesalamine; D019819:Budesonide; D000069285:Infliximab; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone